Tecentriq Triple Combo Under FDA Review for NSCLC Treatment

Genetech has announced that the U.S. Food and Drug Administration (FDA) will be reviewing its Tecentriq (atezolizumab) combined with chemotherapy drugs Abraxane (nab-paclitaxel) and carboplatin for treatment of metastatic non-squamous non-small cell lung cancer (NSCLC). The drug will be for patients without any mutations in the EGFR and ALK genes.   Tecentriq is a checkpoint inhibitor drug that targets […]